Skip to main content
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1978 Jun;3:318–321.

The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.

S Dische, M I Saunders, I R Flockhart
PMCID: PMC2149388  PMID: 209811

Abstract

The amount of misonidazole which may be given to one patient is limited because of the risk of neurotoxicity. The drug may be given with every treatment of a multi-fraction course of radiotherapy or only with some of the treatments. The number of radiotherapy treatments can be reduced or multiple treatments given after each dose of the drug. Experience in 19 patients given daily doses of misonidazole is reported. This is practical regime to be considered for clinical trials of this hypoxic cell sensitizer.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dische S., Saunders M. I., Lee M. E., Adams G. E., Flockhart I. R. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br J Cancer. 1977 May;35(5):567–579. doi: 10.1038/bjc.1977.90. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES